<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773512</url>
  </required_header>
  <id_info>
    <org_study_id>UK2012</org_study_id>
    <secondary_id>IGA 2012 NT/13224</secondary_id>
    <nct_id>NCT01773512</nct_id>
  </id_info>
  <brief_title>The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Czech Ministry of Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>General University Hospital, Prague</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The prediction of extent and risk profile of coronary atherosclerosis based on clinical
           evaluation and non-invasive techniques.

        -  Detailed analysis of plaque volume, plaque composition, risk plaque features and shear
           stress (WSS) changes during lipid lowering therapy (rosuvastatin 40mg) from 3D vessel
           reconstruction.

        -  Prediction of changes in coronary arteries based on changes in non-invasive
           examinations.

        -  Examination of WSS influence on atherosclerosis development and changes of WSS during
           lipid lowering therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The fundamental aim of this project is development of reliable algorithm for detection of
      extent and risk profile of coronary atherosclerosis based on non-invasive examinations
      (carotid ultrasound, examination of retinal vessel, diagnosis of endothelial dysfunction,
      pro-inflammatory markers including new markers of atherosclerosis and gene polymorphisms)
      with maximal effort on diagnosis of vulnerable plaques. The second part of the study is
      prediction of coronary atherosclerosis changes during high-dose lipid-lowering therapy
      (rosuvastatin 40 mg daily). Coronary artery impairment will be examined by up-to date
      technology using the fusion of angiography, intravascular ultrasound and virtual histology
      for 3D coronary artery reconstruction together with information about mechanical properties
      of arteries like a vessel shear stress. This algorithm for non-invasive assessment of
      coronary impairment and its changes during will be used for detection of high risk patients
      (in terms of acute coronary syndrome development) and of patients with low response to statin
      therapy. Further target is detailed assessment of atherosclerosis development and its changes
      during lipid-lowering therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The prediction of plaque volume and plaque composition.</measure>
    <time_frame>The patients will be followed in the study for one year</time_frame>
    <description>The study is looking for non-invasive predictors of plaque volume and plaque composition. The non-invasive predictors include carotid ultrasound, polymorphism in gene for heme-oxygenase 1 and retinal imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of changes in plaque volume and plaque composition</measure>
    <time_frame>The patients will be followed in the study for one year.</time_frame>
    <description>Prediction of changes in plaque composition and plaque volume during lipid lowering therapy based on changes of non-invasive examination.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be using rosuvastatin 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>All patients will be using rosuvastatin 40 mg</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable angina pectoris

        Exclusion Criteria:

          -  age less than 18 or more than 80

          -  renal insufficiency

          -  liver insufficiency

          -  pregnancy or , child potential without contraception

          -  intolerance of statins

          -  rhabdomyolysis or other myopathy in patientÂ´s history

          -  acute coronary syndrome in last 6 weeks

          -  coronary anatomy unsuitable for intravascular ultrasound

          -  active cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Loyola University Hospital</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Kovarnik, MD, PhD</last_name>
      <phone>+420224962687</phone>
      <email>tomas.kovarnik@vfn.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jan Horak, MD, PhD</last_name>
      <phone>+420224962605</phone>
      <email>jan.horak@vfn.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Tomas Kovarnik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Horak, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hana Skalicka, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ales Kral, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ales Linhart, MD, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Martasek, MD, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kovarnik T, Kral A, Skalicka H, Mintz GS, Kralik L, Chval M, Horak J, Skalicka L, Sonka M, Wahle A, Downe RW, Uhrova J, Benakova H, Cernohousova L, Martasek P, Belohlavek J, Aschermann M, Linhart A. The prediction of coronary artery disease based on non-invasive examinations and heme oxygenase 1 polymorphism versus virtual histology. J Invasive Cardiol. 2013 Jan;25(1):32-7.</citation>
    <PMID>23293173</PMID>
  </reference>
  <reference>
    <citation>Sonka M, Downe RW, Garvin JW, Lopez J, Kovarnik T, Wahle A. IVUS-based assessment of 3D morphology and virtual histology: prediction of atherosclerotic plaque status and changes. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6647-50. doi: 10.1109/IEMBS.2011.6091639.</citation>
    <PMID>22255863</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General University Hospital, Prague</investigator_affiliation>
    <investigator_full_name>Tomas Kovarnik</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Intravascular ultrasound</keyword>
  <keyword>Virtual histology</keyword>
  <keyword>Optical coherence tomography</keyword>
  <keyword>Coronary atherosclerosis</keyword>
  <keyword>Statins</keyword>
  <keyword>Retinal imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

